A Japanese study found high remission and continuation rates, plus non-inferior trough levels, after patients with IBD were switched to the infliximab biosimilar CT-P13.

Sandoz's Edward Li explains how biosimilar denosumab pricing could reshape cost-effectiveness, payer access, and gaps in ...

Patients with neovascular age-related macular degeneration (nAMD) who transitioned from off-label bevacizumab to a biosimilar and then to a branded anti-VEGF agent had longer injection intervals ...

A study found no direct trial evidence for natalizumab or its biosimilar in MS and found limited cost-effectiveness vs most ...

Most pediatric and young adult patients with IBD maintained stable disease activity and laboratory markers after switching ...

Analytical characterization supports monoclonal antibody biosimilar approvals and may reduce clinical testing needs, researchers found. As biosimilar development continues to expand across biologic ...

Real-world data shows rituximab biosimilars for membranous nephropathy match remission rates, cut costs, and expand treatment options. A lower-cost biosimilar of rituximab produced remission rates on ...

Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance. We estimate that ...

Biosimilars save billions, but FDA’s new guidance, physician concerns, and Humira switchbacks reveal hurdles to a sustainable US market. Since the first launch in 2015, biosimilars have fundamentally ...

The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to cost-effective therapies. Stakeholders across the US health care system navigated a ...

Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US market entry delays. The final months of 2025 delivered a mix of significant ...

November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets. November 2025 marked a period of significant ...